Yahoo!   My Yahoo!   Mail  
Search   
Sign In
New User? Sign Up
Home > Investing > ARDM.OB > Summary

Aradigm Corp.
(ARDM.OB)

0.1375USD   Down 0.0025 (1.79%)   
At 1:43AM IST
 Aradigm Corp. (OTC BB:ARDM.OB) Delayed quote data 
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Last Trade: 0.1375USD
Trade Time:1:43AM IST
Change:Down 0.0025 (1.79%) 
Prev Close:0.14
Open:0.14
Bid:0.133 x 5000
Ask:0.14 x 5000
1y Target Est:2.25
Day's Range:0.13 - 0.14
52wk Range:0.07 - 0.37
Volume:46,890
Avg Vol (3m):223,465
Market Cap:14.08M
P/E (ttm):N/A
EPS (ttm):-0.194
Div & Yield:N/A (N/A%)
Add ARDM.OB to Portfolio   Download Data

HEADLINES

 
•Aradigm Receives $4 Million Milestone Payment Upon First Commercial Sale of SUMAVEL* DosePro* - Business Wire  - Thu, Feb 4
•Aradigm to Present at Biotech Showcase 2010 on January 12 - Business Wire  - Wed, Jan 6
•Aradigm Lippert/Heilshorn Life Sciences Call scheduled for 12:00 pm ET today - Vcall  - Tue, Dec 15
•Aradigm to Present at the Lippert/Heilshorn Life Sciences Virtual Conference on December 15 - Business Wire  - Thu, Dec 10
•Aradigm Doses First Patient in Long-Term Phase 2 Study of a Novel Inhaled Ciprofloxacin Formulation for the Management of Respiratory Infections in Bronchiectasis - Business Wire  - Mon, Nov 16
•ARADIGM CORP Financials - EDGAR Online Financials  - Fri, Nov 13
•ARADIGM CORP Files SEC form 10-Q, Quarterly Report - EDGAR Online  - Sat, Nov 7
•Emerging Stock Report Initiates Independent Research Coverage On Aradigm Corp. - GlobeNewswire  - Wed, Sep 9
•ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - EDGAR Online  - Fri, Aug 7
•ARADIGM CORP Files SEC form 10-Q, Quarterly Report - EDGAR Online  - Fri, Aug 7
» More Headlines for ARDM.OB...

ANALYST

 
EPS Est (next year) (Dec-09) :-0.14
EPS Est (in 2 years) (Dec-10) :N/A
Avg Rec (current)*:1.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
» Analyst Opinion» Estimates

BUSINESS SUMMARY

 
Aradigm Corporation, a pharmaceutical company, engages in the development and commercialization of drugs delivered by inhalation for the treatment of respiratory diseases by pulmonologists in the United States.

» Full Company Profile